T4090 Eye Drops for Glaucoma and Ocular Hypertension

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Laboratoires Thea

Trial Summary

What is the purpose of this trial?This trial is testing a new treatment called T4090 to see if it is safe for people. The study includes a wide range of participants to ensure the treatment does not cause harm.

Eligibility Criteria

This trial is for individuals with open-angle glaucoma or ocular hypertension in both eyes who have signed an informed consent. It's not suitable for those allergic to the trial medication, pregnant or breastfeeding women, or anyone with recent eye trauma or significant inflammation.

Inclusion Criteria

Both of my eyes have been diagnosed with glaucoma or high eye pressure.

Informed consent dated and signed.

Informed consent dated and signed

+1 more

Exclusion Criteria

Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)

Pregnancy or breast-feeding

I have not had any serious injuries, infections, or inflammation in the last 6 months.

Participant Groups

The study is testing T4090 eye drops containing Kinezodianone R hydrochloride against a placebo to assess their safety in treating patients with ocular hypertension or glaucoma.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: T4090Experimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

named "Vehicle" in the study protocol.